Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-10-21
1999-11-09
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514255, 514256, 514311, 514326, 514331, 514333, 514340, 514365, 514372, 514374, 514403, 514444, 514469, 544237, 544238, 544253, 544333, 544353, 546122, 546134, 546209, 546241, A61K 31445, C07D21344, C07D23730, C07D24102
Patent
active
059815280
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing an oxazolidinone ring. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.
The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded primarily as effective against Gram-positive pathogens because of their particularly good activity against such pathogens.
Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant streptococcus pneumoniae and multiply resistant Enterococcus faecium.
The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with nephrotoxicity and ototoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.
The present inventors have discovered a class of antibiotic compounds containing an oxazolidinone ring which has useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used .beta.-lactans.
We have now discovered a narrow range of compounds that is not suggested by the art and which has good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics. In comparison with compounds described in the art (for example Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165) the compounds also possess a favourable toxicological profile.
Accordingly the present invention provides a compound of the formula (I): ##STR2## wherein: R.sup.1 is hydroxy, chloro, fluoro, (1-4C)alkanesulfonyloxy, amino, azido, (1-4C)alkoxy, (1-4C)alkylthio, (1-4C)alkylaminocarbonyloxy; (1-4C)alkoxy, amino, chloromethyl, dichloromethyl, cyanomethyl, methoxymethyl, acetylmethyl, methylamino, dimethylamino or (1-4C)alkyl; or 2; SO.sub.2 or NR.sup.7 ; (.dbd.O), (1-4C)alkyl, (1-4C)alkanoylamino-(1-4C)alkyl, hydroxy-(1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, AR-oxymethyl, AR-thiomethyl (wherein AR is as defined hereinbelow) or independently as defined for R.sup.7 hereinbelow; independently oxo (.dbd.O), (1-4C)alkyl, (1-4C)alkanoylamino-(1-4C)alkyl, hydroxy-(1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, AR-oxymethyl, AR-thiomethyl (wherein AR is as defined hereinbelow) or independently as defined for R.sup.7 hereinbelow; (2-4C)alkanoyloxy; >C(OH)CHR.sup.a -- (>represents two single bonds) wherein R.sup.a is hydrogen or (1-4C)alkyl; 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, AR (as defined hereinbelow) or a tetrazole ring system (optionally mono-substituted in the 1- or 2- position of the tetrazole ring) wherein the tetrazole ring system is joined to the nitrogen in NR.sup.7
REFERENCES:
patent: 4287351 (1981-09-01), Bourgery et al.
patent: 4346102 (1982-08-01), Langlois et al.
patent: 4476136 (1984-10-01), Dostert et al.
patent: 4705799 (1987-11-01), Gregory
patent: 4942183 (1990-07-01), Gregory et al.
patent: 4948801 (1990-08-01), Carllson et al.
patent: 4977173 (1990-12-01), Brittelli et al.
patent: 5043443 (1991-08-01), Carlson et al.
patent: 5164510 (1992-11-01), Brickner
patent: 5182403 (1993-11-01), Brickner
patent: 5231188 (1993-07-01), Brickner
patent: 5523403 (1996-06-01), Barbachyn
patent: 5529998 (1996-06-01), Habich et al.
patent: 5547950 (1996-08-01), Hutchinson et al.
patent: 5565571 (1996-10-01), Barbachyn et al.
patent: 5574055 (1996-11-01), Borgulya et al.
patent: 5652238 (1997-07-01), Brickner et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 5698574 (1997-12-01), Reidl et al.
patent: 5719154 (1998-02-01), Tucker et al.
patent: 5736545 (1998-04-01), Gadwood et al.
Abstracts: The 1996 ICAAC (Interscience Congress of Antimicrobial Agents and Chemotherapy), New Orleans, 41, (Spe. 15-18, 1996).
Ashtekar, D., et al., "Oxazolidinones, a New Class of Synthetic Antituberculosis Agent: In vitro and in vivo Activities of DuP-721 Against Mycobacterium tuberculosis", Diagn. Microbiol. Infect. Dis., 14, 465-471, (1991).
Barbachyn, M., et al., "Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity", J. Medical Chemistry, 39, 680-685, (1996).
Barbachyn, M., et al., "Synthesis and Antibacterial Activity of New Tropone-Substituted Phenyloxazolidinone Antibacterial Agents. 1. Identification of Leads and Importance of the Tropone Substitution Pattern.", Bioorganic and Medicinal Chemistry Lett., 6, 1003-1008, (1996).
Barbachyn, M., et al., "Synthesis and Antibacterial Activity of New Tropone-Substituted Phenyloxazolidinone Antibacterial Agents. 2. Modification of the Phenyl Ring--the Potentiating Effect of Fluorine Substitution on In Vivo Activity.", Bioorganic and Medicinal Chemistry Lett., 6, 1009-1014 (1996).
Barry, A., et al., "In Vitro Evaluation of DuP 105 and DuP 721, Two New Oxazolidinone Antimicrobial Agents", Antimicrobial Agents and Chemotherapy, 32, 150-152, (1988).
Borthwick, A., et al., "5-(Acetamidomethyl)-3-Aryldihydrofuran-2-ones, and 5-(Acetamidomethyl)-3-Aryltetrahydrofuran-2-ones, Two New Classes of Antibacterial Agents", Med. Chem. Res., 6, 22-27, (1996).
Brickner, S., et al., "Oxazolidinone Antibacterial Agents", Current Pharmaceutical Design, 2, 175-194, (1996).
Brickner, S., et al., "Synthesis and Antibacterial Activity of U-100592 and U-100766, Tow Oxazolidinone Antibactieral Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections", J. Medical Chemsitry, 39, 673-679, (1996).
Brumfitt, W., et al., "Antibacterial Oxazolidinones: In Vitro Activity of a New Analogue, E3709", Diagn. Microbiol. Infect. Dis., 15, 621-625, (1992).
Brumfitt, W., et al., "In-vitro Microbiological Activities of DuP 105 and DuP 721, Novel Synthetic Oxazolidinones", J. Antimicrobial Chemotherapy, 21, 711-720, (1988).
Brumfitt, W., et al., "Variation in Response of Gram-Positive cocci to the Combination DuP 721 and ciprofloxacin", J. Antimicrob. Chemotherapy, 24, 465-466, (1989).
Daly, J., et al., "Activity and Mechanism of Action DuP 105 and DuP 721, New Oxazolidinone Compounds", J. Antimicrobial Chemotherapy, 21, 721-730, (1988).
Denis, A., et al., "5-Aryl-beta,gamma Butenolide, A New Class of Antibacterial Derived from the N-Aryl Oxazolidinone DUP 721", Bioorganic and Medicinal Chemistry Lett., 4, 1925-1930, (1994).
Dostert, P., et al., "Structural Modifications in Oxazolidinone Series Leading to Type A or B Selective Monoamine Oxidase Inhibitors", Int. Congress Series; Excerpta Medica, 564, 197-208, (1982).
Eliopoulos, G., et al., "In Vitro Activities of New Oxazolidinone Antimicrobial Agents against Enterococci", Antimicrobial Agents and Chemotherapy, 40, 1745-1747, (1996).
Eustice, D., et al., "An Automated Pulse Labelling Method for Structure-A
Richter Johann
Solola Taofiq A
Zeneca Limited
LandOfFree
Antibiotic oxazolidinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibiotic oxazolidinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibiotic oxazolidinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456228